Catalog No.
Product Name
Application
Product Information
Citations
-
IL-15 Agonist
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain fused with human IgG1 Fc, serving as an IL-15 superagonist. This compound forms a complex with the IL-15 antibody Nogapendekin alfa, enhancing anti-CD20 monoclonal antibody-mediated natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept significantly promotes degranulation and interferon-gamma (IFNγ) production in NK cells, making it a valuable tool for research in immunotherapy and cancer treatment strategies. -
IL-17 Modulator
IL-17 Modulator 4 is a proagent of IL-17 Modulator 1, serving as an IL-17 inhibitor targeting the interleukin-17 pathway. This compound exhibits potent modulation of IL-17A and is significant for research into IL-17A mediated diseases, including various inflammatory and autoimmune conditions, as well as infectious diseases and cancer. Its application in preclinical studies may enhance understanding of the therapeutic potential in these pathologies. -
IL-2R Agonist
Nemvaleukin alfa is an IL-2 fusion protein that selectively targets intermediate-affinity IL-2 receptors (IL-2R). Its mechanism involves activating natural killer (NK) cells and effector T cells, thereby enhancing immune responses. This reagent is utilized in cancer research to investigate immune modulation and therapeutic strategies aimed at improving anti-tumor immunity. -
IL-22 Activator
Efmarodocokin alfa is a fusion protein comprising human IL-22 and the IgG4 crystallizable fragment, functioning primarily as an IL-22 activator. This reagent enhances IL-22 signaling pathways, contributing to the modulation of immune responses. It is particularly relevant for research applications focused on severe COVID-19 pneumonia, facilitating studies on therapeutic strategies that leverage IL-22 in inflammation and tissue repair processes. -
IL-17 Modulator
IL-17 modulator 3 is a specific IL-17 modulator that targets the IL-17 signaling pathway, playing an essential role in immune regulation. It exhibits potential anti-inflammatory properties and is valuable for research into inflammatory conditions, cancer, and autoimmune diseases. This compound offers insights into the modulation of IL-17 related pathways in various biological contexts. -
IL6/STAT3 Inhibitor
Angoline is a selective inhibitor of the IL6/STAT3 signaling pathway, demonstrating an IC50 of 11.56 μM. It effectively inhibits the phosphorylation of STAT3, leading to reduced expression of target genes associated with cancer progression. This compound is valuable for research applications focused on cancer biology and the modulation of inflammatory responses. -
IL-17A Antagonist
Simepdekinra is an IL-17A antagonist that plays a crucial role in modulating inflammatory responses. It demonstrates significant potential in the research of moderate to severe plaque-type psoriasis by inhibiting the activity of IL-17A, a key cytokine involved in the pathogenesis of this condition. Its application in preclinical studies provides valuable insights into therapeutic strategies targeting autoimmune skin diseases. -
IL-2/IL-2Rα Inhibitor
SP4206 is an inhibitor of the IL-2/IL-2Rα interaction, exhibiting high-affinity binding to IL-2 with a dissociation constant (Kd) of 70 nM. By effectively blocking the interaction with its natural receptor IL-2Rα, which has a Kd of 10 nM, SP4206 has significant potential for modulating immune responses. This compound is valuable for research applications focused on autoimmune diseases, cancer immunotherapy, and enhancing our understanding of IL-2-mediated signaling pathways. -
IL-18 Inhibitor
NSC80734 is an IL-18 inhibitor that effectively disrupts the binding of human IL-18 to ectromelia virus IL-18 binding protein (IL-18BP). This compound inhibits the IL-18-mediated production of interferon-gamma (IFN-γ), making it a valuable tool for studying the role of IL-18 in inflammatory processes and immune responses. NSC80734 is applicable in research focusing on cytokine signaling and related biological pathways. -
IL-17C/IL-17RE Interaction Inhibitor
Lib2-1 is a macrocyclic peptide that functions as an inhibitor of the IL-17C/IL-17RE interaction. This compound demonstrates significant potential in modulating inflammatory responses, making it a valuable tool in the study of autoimmune and inflammatory diseases. Researchers can utilize Lib2-1 to investigate the underlying mechanisms of IL-17C signaling and its implications in various pathological conditions. -
IL-15 Agonist
Nogapendekin alfa (his tag) is a soluble protein subunit of a human interleukin-15 variant, acting as a potent superagonist of IL-15. It enhances the proliferation and survival of immune cells, making it valuable for various immuno-oncology studies. In combination with Inbakicept, Nogapendekin alfa forms the IL-15 cytokine-antibody fusion protein N-803, which has demonstrated the ability to reduce tumor burden through the activation of natural killer (NK) cells and CD8+ T cells. This reagent is instrumental in research applications targeting cancer immunotherapy and immune response modulation. -
IL-17A Antagonist
IL-17A antagonist 3 is a selective inhibitor of IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. This compound effectively blocks the interaction of IL-17A with its receptor, leading to reduced downstream inflammatory responses. It is applicable in research focused on the pathophysiology of conditions such as psoriasis, rheumatoid arthritis, and other IL-17-mediated disorders. -
IL-17A Modulator
IL-17A modulator-2 selectively targets interleukin-17A (IL-17A), functioning as a potent inhibitor with a pIC50 of 8.3. This compound effectively modulates the biological activity of IL-17A, making it valuable for research into a variety of conditions linked with IL-17A dysregulation. Applications include investigations into autoimmune diseases, cancers, and neurodegenerative disorders where IL-17A plays a significant role in pathogenesis. -
IL-18 Inhibitor
NSC61610 is an inhibitor of interleukin-18 (IL-18) that disrupts the binding of human IL-18 to the ectromelia virus IL-18 binding protein (IL-18BP). It effectively inhibits the formation of the hIL-18:ectvIL-18BP complex, demonstrating an IC50 of approximately 6 µM. This compound is valuable for research applications involving inflammatory responses and the study of viral interactions with host immune mechanisms. -
IL-17A Modulator
IL-17A modulator-1 is a selective modulator of interleukin-17A (IL-17A) that inhibits its biological activity with a pIC50 of 8.2. This compound is valuable for research into diseases associated with dysregulation of IL-17A, including autoimmune disorders, cancers, and neurodegenerative diseases. Its ability to modulate IL-17A activity makes it a pertinent tool for studies investigating immune responses and therapeutic interventions. -
IL-1 Inhibitor
Lys-D-Pro-Thr is an IL-1β analogue, specifically targeting the positions 193-195 of the IL-1β protein. It acts as a potent inhibitor of IL-1, playing a critical role in regulating inflammatory responses. This reagent is valuable for research applications focused on inflammatory pathways, autoimmune diseases, and the modulation of cytokine signaling. -
IL-17A Inhibitor
Navepdekinra is a potent inhibitor of interleukin-17A (IL-17A), with an IC50 of 10.81 nM. By disrupting the interaction between IL-17A and its receptor, Navepdekinra effectively suppresses downstream pro-inflammatory signaling pathways. This compound has demonstrated efficacy in reducing arthritis symptoms in a collagen-induced arthritis rat model and is applicable to research in psoriasis, psoriatic arthritis, and ankylosing spondylitis. -
FAPα/IL-2Rβγ Immunocytokine
Simlukafusp alfa is an immunocytokine composed of an antibody targeting fibroblast activation protein α (FAPα) and a variant of interleukin-2 (IL-2) that selectively engages the IL-2 receptor βγ chain. This unique structure enhances the immune response against FAPα-expressing tumors while promoting T-cell activation and proliferation. Simlukafusp alfa is suitable for research applications focused on cancer immunotherapy and the study of tumor microenvironments, particularly in evaluating the efficacy of targeted immune modulation. -
IL-1 Antagonist
Goflikicept is an IL-1 antagonist that functions as a fusion protein, selectively binding to and neutralizing both IL-1β and IL-1α. This mechanism of action positions Goflikicept as a valuable tool for research focused on inflammatory conditions, particularly in the context of ST-segment elevation myocardial infarction (STEMI). Its ability to modulate IL-1 signaling pathways makes it relevant for studying various cardiovascular and autoimmune disorders. -
IL-23R Inhibitor
IL-23R inhibitor peptide-1 is a potent interleukin-23 receptor inhibitor with an IC50 of 0.0069 μM. It is designed to modulate the signaling pathway of IL-23, which plays a critical role in the pathogenesis of various autoimmune diseases. This reagent is suitable for research applications focused on inflammatory responses and therapeutic strategies targeting IL-23 signaling. -
IL-17 Modulator
(R)-IL-17 modulator 4 is a selective modulator of IL-17, functioning as a proagent for IL-17 modulator 1, a potent and orally active IL-17 inhibitor. This compound exhibits significant biological activity in the modulation of IL-17A signaling pathways, making it valuable in the study of IL-17A mediated diseases. Research applications include investigating its role in inflammation, autoimmune disorders, infectious diseases, cancer, and precancerous syndromes. -
IL-2 Inhibitor
IL-2-IN-1 is a potent inhibitor of interleukin-2 (IL-2), exhibiting an IC50 value of 1978 nM. It demonstrates significant antiproliferative activity, making it a valuable tool for research in immune modulation and cytokine signaling. This compound is ideal for studies focused on T cell regulation and potential therapeutic applications in autoimmune diseases and cancers linked to IL-2 signaling. -
IL-20/PRINS Inhibitor
Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. This compound demonstrates significant immune modulation, effectively reducing the proliferation rate of skin cells in psoriasis. It serves as a valuable tool for investigating inflammatory skin disorders and potential therapeutic strategies in related research applications. -
IL-1β Inhibitor
IL-1β-IN-2 is a potent inhibitor of interleukin-1 beta (IL-1β), a key mediator in inflammatory processes. This cannabigerol derivative exhibits significant anti-inflammatory and analgesic effects, making it a valuable tool for research into conditions driven by IL-1β signaling. IL-1β-IN-2 is suitable for studies focused on inflammatory diseases and pain management, aiding in the understanding and development of therapeutic strategies targeting IL-1β. -
IL-17 Modulator
IL-17 Modulator 1 disodium is a potent inhibitor targeting the IL-17 signaling pathway. This compound demonstrates significant biological activity in mitigating inflammatory responses, making it valuable for research applications related to autoimmune conditions such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. Its oral bioavailability further enhances its utility in preclinical studies aimed at understanding and developing therapies for IL-17 associated diseases. -
IL-1β Inhibitor
IL-1β-IN-1 is a selective inhibitor of interleukin-1 beta (IL-1β), a key cytokine involved in inflammatory processes. This compound demonstrates significant anti-inflammatory and analgesic effects, making it a valuable tool in research focused on chronic inflammatory conditions and pain management. Its potency and specificity for IL-1β allow for detailed studies on its biological roles and therapeutic applications. -
IL-17 Inhibitor
IL-17-IN-2 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.4 μM, as demonstrated in both HTRF and NHK assays. This compound effectively disrupts IL-17 signaling, making it valuable for research related to inflammatory diseases and immune response modulation. Its significant biological activity allows for exploration in therapeutic contexts targeting IL-17-mediated pathways. -
Anti-IL-17C Antibody
MOR-106 is a humanized anti-IL-17C IgG1 monoclonal antibody that targets interleukin-17C, a cytokine involved in inflammatory responses. By binding specifically to IL-17C, MOR-106 inhibits the NF-κB signaling pathway, demonstrating an IC50 of 59 pM for human IL-17C and 55 pM for mouse IL-17C. This reagent effectively reduces skin inflammation and associated inflammatory factors in preclinical models of psoriasis and atopic dermatitis, making it a valuable tool for research into inflammatory skin disorders. -
IL-17 Modulator
IL-17 Modulator 4 Sulfate targets the IL-17 signaling pathway, functioning as a proagent of IL-17 Modulator 1. This compound exhibits potent modulatory effects on IL-17A, making it a valuable tool for investigating IL-17A mediated diseases. Its applications extend across various fields, including inflammation, autoimmune disorders, infectious diseases, cancer, and precancerous syndromes, facilitating a deeper understanding of these conditions. -
Anti-IL-15RA Antibody
Larnefpendekin alfa is an anti-IL-15RA antibody designed to target and inhibit the interleukin-15 receptor alpha (IL-15RA). This fusion protein plays a pivotal role in modulating immune responses by interfering with IL-15 signaling pathways. Its primary applications include investigations into immune system regulation, potential therapeutic avenues in autoimmune diseases, and cancer immunotherapy. This reagent is valuable for research focused on cytokine interactions and immune cell activation. -
IL-2 Antibody Inhibitor
Balekafusp alfa is an IgG1K human antibody specifically targeting interleukin-2 (IL-2). It exhibits anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. This reagent can aid in investigating the immunological mechanisms of IL-2 and its role in tumor progression. Additionally, researchers can utilize it to explore potential applications in immunotherapy and the modulation of immune responses. -
IL-17 Inhibitor
IL-17-IN-5 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.1 μM. This compound is designed for research applications related to inflammatory diseases, facilitating the study of IL-17's role in various pathophysiological processes. IL-17-IN-5 can aid in the development of therapeutic strategies targeting IL-17 signaling pathways. -
IL-1 Inhibitor
Triptoquinone B is a sesquiterpene alkaloid that functions as an interleukin-1 inhibitor. It exhibits significant inhibitory effects on the release of interleukin 1α and 1β from human peripheral mononuclear cells, making it a valuable reagent for studies focused on inflammatory processes and cytokine signaling. This compound is useful for research into immune responses and related therapeutic applications. -
Anti-IL-1β Antibody
Abdakibart is a humanized IgG4 monoclonal antibody that selectively targets IL-1β, a key cytokine involved in the inflammatory response. This reagent is particularly valuable for research applications related to inflammatory diseases, including type 2 diabetes. By inhibiting IL-1β, Abdakibart can help elucidate the pathways involved in inflammation and contribute to the development of novel therapeutic strategies. -
IL-17A Modulator
IL-17A modulator-3 is a selective modulator targeting IL-17A. This compound demonstrates effective inhibition of the IL-17A/A receptor complex with an IC50 value of less than 10 μM. It is suitable for research applications related to inflammation, cancer biology, and autoimmune disorders, providing valuable insights into these critical areas of study. -
Anti-IL-1β Antibody
SSGJ-613 is a fully human monoclonal antibody that targets interleukin-1 beta (IL-1β). This reagent is designed for the investigation of inflammatory conditions, particularly gouty arthritis, by inhibiting the activity of IL-1β, a key mediator in the inflammatory response. Its application extends to research focused on understanding the role of IL-1β in various diseases and therapeutic development. -
IL-17 modulator
IL-17 modulator 6 is a potent inhibitor of Interleukin 17 (IL-17) with a pIC50 of 9.1. This compound effectively modulates IL-17 signaling and is utilized in the study of inflammatory and autoimmune diseases. Researchers may employ IL-17 modulator 6 to explore therapeutic strategies targeting IL-17 pathways. -
IL-2 Fusion Protein
Lecomkafusp alfa is an IL-2 fusion protein designed to enhance immunomodulatory activity. It consists of human IL-2 linked via a protease-cleavable peptide to a humanized single-domain VHH fragment that targets albumin. This compound demonstrates significant antineoplastic properties, making it a valuable tool in cancer immunotherapy research and the exploration of novel therapeutic strategies. -
Anti-IL-17A Antibody
HB-0017 is a humanized IgG1κ monoclonal antibody that specifically targets interleukin-17A (IL-17A). This antibody effectively inhibits IL-6 secretion induced by IL-17A with an IC50 value of 2.09 nM. HB-0017 has demonstrated significant efficacy in reducing ear thickness in a psoriasis-like mouse model induced by Imiquimod, as well as alleviating inflammation in models of IL-17A-induced arthritis and air pouch inflammation. -
Anti-IL-17A Antibody
Velvakiment is a humanized VHH nanobody that specifically targets interleukin-17A (IL-17A). This antibody is valuable for investigating autoimmune diseases, including multiple sclerosis and rheumatoid arthritis, by elucidating the role of IL-17A in inflammatory pathways. Its specificity and affinity facilitate advanced research on therapeutic interventions aimed at modulating IL-17A activity in various disease contexts. -
Anti-IL-17RB Antibody
Ponumkibart is a humanized IgG4κ antibody specifically designed to target the interleukin-17 receptor B (IL-17RB). This antibody serves as a critical tool for investigating the role of IL-17 signaling in various pathologies, including autoimmune diseases and inflammatory conditions. Its application in research includes the study of immune response modulation and the development of therapeutic strategies targeting IL-17 pathways. -
Anti-IL-13 Antibody
Zumilokibart is a humanized IgG1κ antibody that specifically targets interleukin-13 (IL-13). This antibody is designed to inhibit the biological activity of IL-13, a cytokine implicated in various allergic and inflammatory diseases. It is suitable for research applications focused on asthma, allergic rhinitis, and other conditions where IL-13 plays a pivotal role in pathophysiology. -
IL-17 Modulator
IL-17 Modulator 5 is a potent inhibitor targeting interleukin-17 (IL-17) with an IC50 of 1 nM. This compound exhibits significant inhibition of IL-17 associated pathways, playing a critical role in inflammatory responses. It is applicable in research on autoimmune diseases and inflammatory disorders, facilitating investigations into therapeutic avenues for conditions such as psoriasis and rheumatoid arthritis. -
IL-2/IL-2Rα Antagonist
Ro26-4550 TFA is a low micromolar antagonist of the interleukin-2 (IL-2) and IL-2 receptor alpha (IL-2Rα) interaction, exhibiting an IC50 value of 3 μM. This compound serves as a valuable tool for investigating the IL-2 signaling pathway, making it relevant for studies in immunology and cancer research. Its ability to inhibit IL-2 signaling can aid in the understanding of immune responses and the development of therapeutic strategies targeting IL-2 mediated pathways. -
IL-10 Fusion Protein
Vimekofusp is a recombinant IL-10 fusion protein that specifically targets IL10RA and IL10RB receptors. This agent exhibits potent immunomodulatory activity by enhancing anti-inflammatory responses and promoting regulatory T cell functions. It is primarily utilized in research applications focusing on autoimmune diseases, chronic inflammation, and therapeutic strategies aimed at modulating the immune system. -
IL-2 Fusion Protein
Efpixileukin alfa is a fusion protein consisting of a human IL-2 variant connected at the C-terminus to a human immunoglobulin G1 (IgG1) Fc fragment. This immunomodulator enhances T-cell proliferation and activation, making it valuable for therapeutic applications in cancer immunotherapy and autoimmune diseases. Research involving Efpixileukin alfa focuses on its potential to improve immune responses and its role in modulating the tumor microenvironment. -
IL-23 Inhibitor
IL-23 cyclic peptide inhibitor 105 targets the interleukin-23 (IL-23) pathway, serving as a specific inhibitor of this pro-inflammatory cytokine. It exhibits significant potential in modulating inflammatory responses associated with disorders such as inflammatory bowel disease (IBD). This compound is a valuable tool for researchers investigating the role of IL-23 in various inflammatory conditions and developing therapeutic strategies targeting IL-23 signaling. -
IL-17 Modulator
IL-17 Modulator 1 is a small molecule that selectively targets the IL-17 signaling pathway. This compound exhibits high efficacy in modulating IL-17 activity, making it valuable for studying inflammatory diseases. It is particularly relevant in research focusing on psoriasis, ankylosing spondylitis, and psoriatic arthritis, providing insights into mechanisms of disease prevention and treatment. -
IL-17 Inhibitor
IL-17-IN-4 is a potent IL-17 inhibitor with an IC50 of less than 0.1 μM, making it a valuable tool for investigating the role of IL-17 in inflammatory diseases. This compound can facilitate research aimed at understanding the mechanisms of inflammation and the therapeutic potential of IL-17 modulation in conditions such as rheumatoid arthritis and psoriasis. Its high potency enables effective studies of IL-17 signaling pathways in various biological contexts. -
IL-17 Modulator
IL-17 modulator 8 is an orally active modulator targeting interleukin-17 (IL-17). This compound significantly reduces pro-inflammatory cytokines such as IL-6 and IFN-γ, as well as edema. IL-17 modulator 8 is applicable in research focused on arthritis and related inflammatory diseases.
